TITLE:
Current Indications for IL-1 Inhibition in Rheumatology
AUTHORS:
Soukaina Zaher, Kawtar Nassar, Ahlam Ajerouassi, Wafae Rachidi, Saadia Janani
KEYWORDS:
Interleukin 1, Anti-Interleukin 1, Auto-Inflammatory Disease, Anakinra, Canakinumab, Rilonacept
JOURNAL NAME:
Open Journal of Rheumatology and Autoimmune Diseases,
Vol.15 No.4,
November
28,
2025
ABSTRACT: Interleukin-1 pro-inflammatory cytokines orchestrate local and systemic inflammatory responses in several diseases. Three therapeutic agents for reducing the activities of IL-1 are currently available. Conditions effectively treated with IL-1 blocking agents range from classical rheumatic diseases to autoinflammatory syndromes. In addition, IL-1 antagonism is also effective against other very common diseases, namely cardiovascular disease and type 2 diabetes, which are also co-morbidities, frequently found in patients with rheumatic diseases. Therefore, inhibition of IL-1 may provide clinical benefits beyond the efficacy of osteoarticular manifestations. The purpose of this article is to review the indications for anti-interleukins 1 in rheumatology.